Market Closed -
Toronto S.E.
07:19:37 25/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.02
CAD
|
-42.86%
|
|
-42.86%
|
-63.64%
|
Fiscal Period: Januar |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
17.54
|
26.78
|
19.25
|
32.76
|
15.14
|
11.84
|
Enterprise Value (EV)
1 |
5.751
|
23.32
|
19.54
|
32.87
|
15.39
|
12.46
|
P/E ratio
|
-3.28
x
|
-6.09
x
|
-3.11
x
|
0.18
x
|
-0.18
x
|
-1.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
451
x
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
148
x
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-0.73
x
|
-2.58
x
|
-1.43
x
|
-30.8
x
|
-19.5
x
|
-15.2
x
|
EV / FCF
|
1.13
x
|
-5.91
x
|
13.8
x
|
-1.83
x
|
-138
x
|
-21
x
|
FCF Yield
|
88.2%
|
-16.9%
|
7.22%
|
-54.6%
|
-0.72%
|
-4.76%
|
Price to Book
|
-2.38
x
|
-2.61
x
|
-1.26
x
|
0.19
x
|
0.17
x
|
0.14
x
|
Nbr of stocks (in thousands)
|
1,67,089
|
1,67,389
|
1,67,389
|
1,67,999
|
1,68,239
|
1,69,129
|
Reference price
2 |
0.1050
|
0.1600
|
0.1150
|
0.1950
|
0.0900
|
0.0700
|
Announcement Date
|
31/05/18
|
30/05/19
|
26/06/20
|
31/05/21
|
26/05/22
|
31/05/23
|
Fiscal Period: Januar |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0389
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-7.842
|
-9.034
|
-13.63
|
-1.068
|
-0.7887
|
-0.8207
|
EBIT
1 |
-7.854
|
-9.042
|
-13.63
|
-1.07
|
-0.7906
|
-0.8342
|
Operating Margin
|
-20,204.72%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.112
|
-8.641
|
-13.25
|
190.1
|
-85.04
|
-7.332
|
Net income
1 |
-5.086
|
-4.393
|
-6.184
|
190.1
|
-85.04
|
-7.332
|
Net margin
|
-13,084.82%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0320
|
-0.0263
|
-0.0369
|
1.112
|
-0.5055
|
-0.0435
|
Free Cash Flow
1 |
5.073
|
-3.946
|
1.411
|
-17.96
|
-0.1112
|
-0.5933
|
FCF margin
|
13,051.71%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/05/18
|
30/05/19
|
26/06/20
|
31/05/21
|
26/05/22
|
31/05/23
|
Fiscal Period: Januar |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
0.29
|
0.11
|
0.25
|
0.63
|
Net Cash position
1 |
11.8
|
3.46
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.021
x
|
-0.0986
x
|
-0.3165
x
|
-0.7619
x
|
Free Cash Flow
1 |
5.07
|
-3.95
|
1.41
|
-18
|
-0.11
|
-0.59
|
ROE (net income / shareholders' equity)
|
-135%
|
1,152%
|
127%
|
239%
|
-64%
|
-8.44%
|
ROA (Net income/ Total Assets)
|
-40.7%
|
-60.8%
|
-166%
|
-0.74%
|
-0.37%
|
-0.59%
|
Assets
1 |
12.51
|
7.227
|
3.723
|
-25,581
|
22,946
|
1,233
|
Book Value Per Share
2 |
-0.0400
|
-0.0600
|
-0.0900
|
1.040
|
0.5400
|
0.4900
|
Cash Flow per Share
2 |
0
|
0
|
0.0100
|
0
|
0
|
0
|
Capex
1 |
0.01
|
0
|
-
|
-
|
-
|
-
|
Capex / Sales
|
22.44%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/05/18
|
30/05/19
|
26/06/20
|
31/05/21
|
26/05/22
|
31/05/23
|
|
1st Jan change
|
Capi.
|
---|
| -63.64% | 2.47M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|